Abstract
Although there has been much debate about the uptake and effects of predictive testing for common cancers, such as breast and colon cancer, little has been published on the more classical tumour predisposing conditions, such as von Hippel-Lindau disease and familial adenomatous polyposis. Since 1990 the genetics departments in Manchester and Cambridge have had a genetic register for cancer predisposing syndromes and presymptomatic testing for these conditions has been offered once this has become possible. To investigate the factors that might influence uptake of genetic testing in familial cancer syndromes we have reviewed our experience. Demand for predictive testing has generally been high, but men had a lower uptake (77%) than a comparable group of women (93%) (p < 0.01).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Craufurd D., Dodge A., Kerzin-Storrar L., Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet. 1989 Sep 9;2(8663):603–605. doi: 10.1016/s0140-6736(89)90722-8. [DOI] [PubMed] [Google Scholar]
- Evans D. G., Guy S. P., Thakker N., Armstrong J. G., Dodd C., Davies D. R., Babbs C., Clancy T., Warnes T., Sloan P. Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis. Gut. 1993 Oct;34(10):1389–1393. doi: 10.1136/gut.34.10.1389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
- Harper P. S. Insurance and genetic testing. Lancet. 1993 Jan 23;341(8839):224–227. doi: 10.1016/0140-6736(93)90080-z. [DOI] [PubMed] [Google Scholar]
- Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381. doi: 10.1093/brain/111.6.1355. [DOI] [PubMed] [Google Scholar]
- Lynch H. T., Watson P., Conway T. A., Lynch J. F., Slominski-Caster S. M., Narod S. A., Feunteun J., Lenoir G. DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med. 1993 Sep 13;153(17):1979–1987. [PubMed] [Google Scholar]
- MacDonald F., Morton D. G., Rindl P. M., Haydon J., Cullen R., Gibson J., Neoptolemos J. P., Keighley M. R., McKeown C. M., Hultén M. Predictive diagnosis of familial adenomatous polyposis with linked DNA markers: population based study. BMJ. 1992 Apr 4;304(6831):869–872. doi: 10.1136/bmj.304.6831.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maher E. R., Iselius L., Yates J. R., Littler M., Benjamin C., Harris R., Sampson J., Williams A., Ferguson-Smith M. A., Morton N. Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991 Jul;28(7):443–447. doi: 10.1136/jmg.28.7.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schneider K. A., Patenaude A. F., Garber J. E. Testing for cancer genes: decisions, decisions. Nat Med. 1995 Apr;1(4):302–303. doi: 10.1038/nm0495-302. [DOI] [PubMed] [Google Scholar]
- Struewing J. P., Lerman C., Kase R. G., Giambarresi T. R., Tucker M. A. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):169–173. [PubMed] [Google Scholar]
- Varley J. M., McGown G., Thorncroft M., Tricker K. J., Teare M. D., Santibanez-Koref M. F., Martin J., Birch J. M., Evans D. G. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet. 1995 Dec;32(12):942–945. doi: 10.1136/jmg.32.12.942. [DOI] [PMC free article] [PubMed] [Google Scholar]